uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know

2026-02-27 10:49:58 ET

Investment Overview

Shares of the Amsterdam, Netherlands based gene therapy specialist drug developer uniQure N.V. ( QURE ) were in freefall yesterday, dropping by >30% as the market digested comments made by FDA commissioner Dr Marty Makary during an interview with CNBC, that many observers believe may have referenced UniQure's therapy AMT-130, indicated to treat Huntington's Disease....

Read the full article on Seeking Alpha

For further details see: